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abstRact
IntroductIon: Diabetes mellitus and the prediabetic state 
are associated with a number of skin manifestations. This 
study is a systematic review of the following manifestations: 
acanthosis nigricans (AN), skin tags (ST), diabetic dermo­
pathy (DD), rubeosis faciei (RF), pruritus (PR), granuloma an­
nulare (GA), necrobiosis lipoidica (NL), scleroedema diabeti­
corum (SD) and bullosis diabeticorum (BD). These conditions 
possibly relate to underlying diabetogenic mechanisms.  
Our aim was to determine whether skin signs are feasible as 
cutaneous markers for the prediabetic or diabetic state. 
Methods: Data were collected from the databases PubMed, 
Embase and Cochrane. Articles were excluded if the popula­
tions presented with comorbidities or received treatment 
with drugs affecting the skin. Also, animal studies, studies 
with poor methodology and pilot studies were excluded.
results: Among the 34 included original articles, an associ­
ation with diabetes was shown as follows: in eight articles 
with AN, five articles with ST, three articles with GA, two ar­
ticles with NL, PR and SD respectively and in one article with 
RF. Three papers indirectly showed an association of DD 
with diabetes. Association between bullous skin lesions and 
diabetes was only documented by case reports and case  
series.
conclusIon: The results indicate a benefit of diabetes 
screening in individuals presenting with AN, ST or BD. Fur­
ther studies are required to enlighten a possible association 
with RF, GA, SD or NL. Until such studies are available, it is 
advisable to screen individuals with the skin lesions pre­
sented by measuring their glycated haemoglobin.
Cutaneous manifestations are seen in a minimum of 
30% of diabetics during the course of their illness, and 
some may even appear before the diagnosis of diabetes 
mellitus (DM) is confirmed [1­4]. Besides being markers 
of DM, skin signs may possibly play a central role in re­
ducing the complications associated with diabetes as 
they may improve the motivation of patients and phys­
icians towards disease management [5, 6]. Epidemio­
logical data strongly suggest that type 2 diabetes melli­
tus (T2DM) is expanding at an epidemic rate; and it has 
been estimated that the number of diabetics will reach 
250­300 million globally by 2025 [7]. 
The aim of this study was to determine whether 
skin signs are feasible as cutaneous markers for the pre­
diabetic state as well as overt DM.
mEthOds
A systematic search was conducted to identify any spe­
cific cutaneous manifestations of DM (Figure 1A). For 
this purpose, the databases PubMed, Embase and 
Cochrane were used. The search strategy is shown in 
Figure 1B. The search was conducted in accordance with 
the PRISMA guidelines and following the PICO model [8], 
and the final search date was 5 November 2015. We ex­
cluded studies of populations with confounding condi­
tions like malignancies, thyroiditis, gestational diabetes 
and treatment with drugs affecting the skin. We also ex­
cluded animal studies, studies with poor methodology, 
pilot studies and studies focusing on more than one  
cutaneous manifestation. The included articles were 
screened for relevant cross­references. The selection 
process resulted in a total of 34 articles (table 1).
REsUlts
acanthosis nigricans
Acanthosis nigricans (AN) was first recognised in 1889 by 
a German dermatologist [9]. Initially, AN was thought to 
appear among obese and overweight individuals, but it 
was later clarified that the condition was linked to in­
creased levels of insulin, which stimulates keratinocytes 
and dermal fibroblasts through insulin­like growth factor 
(IGF) [6, 10, 11]. As a consequence, thickened and 
hyper pigmented velvety skin develops in body folds, 
mostly the axillae and flexural areas of the posterior 
neck (Figure 2A and Figure 2B). The literature supports a 
higher frequency of AN among the darker­skin coloured 
populations [6, 10­13]. It is more difficult to detect AN in 
fair­skinned people, where the condition may go unde­
tected until overt DM develops. Mostly, the posterior 
neck and intertriginous areas are involved, but it can 
also be observed on the knuckles or elbows. AN is often 
seen in cases of hyperinsulinaemia, and therefore it may 
also be considered a cutaneous manifestation of the 
prediabetic state [11, 13]. Studies repeatedly find a  
higher frequency of AN  among females [12­15], and one 
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study found it to be an independent risk factor for in­
sulin resistance in overweight Hispanic children [16]. 
Weight­loss along with increased physical activity allevi­
ates the condition by reducing the circulating insulin  
level [6, 17]. Assigning the diagnosis of AN and empha­
sising its relation to insulin resistance and possible ways 
to improve the condition may motivate patients to im­
prove their lifestyle [11]. Screening for AN is a non­inva­
sive procedure, and suggested optimal screening is initi­
ated at the age of five and repeated every second year 
for individuals with multiple risk factors such as a family 
history of T2DM, ethnicity and obesity [13]. It is also im­
portant to keep in mind that there are other aetiologies 
to AN, including malignancies [6, 10].
skin tags
These common skin lesions were first described in rela­
tion to DM in 1951 [18]. Skin tags (ST), also named acro­
chordons, appear as small and soft skin tumours which 
are often located on the lateral aspects of the neck, 
back, axilla, trunk and face (Figure 2B) [19]. Of the fibro­
epithelial tumours of the skin,  ST are considered the 
most common [20]. Hyperinsulinaemia stimulates the 
IGF­I receptor, which has a tissue proliferative effect re­
sulting in ST. 
Therefore, individuals with ST are observed to have 
hyperinsulinaemia and glycated haemoglobin (HbA1c) 
levels at the high end of the normal range [21]. There 
are significantly more ST cases in the diabetic population 
than among normoglycaemic individuals [20]. As with 
AN, the ST population presents with a significantly  
higher body mass index (BMI), especially when their 
medical history indicates the presence of additional dia­
betogenic risk factors [19, 20]. A positive correlation has 
been found between the total number of ST and mean 
fasting plasma glucose. Patients with more than 30 ST 
are at an increased risk of developing DM, and females 
with ST beneath their breasts are particularly prone to 
developing DM [19]. It seems that ST may have a higher 
prognostic value for DM than obesity [19]. It is impor­
tant to stress that hypertension, hyperlipidaemia, ath­
erosclerosis and AN appear at a much higher rate in the 
ST population [21­23]. 
diabetic dermopathy
The condition was first described by the Swedish phys­
ician Hans Melin in 1964 [24] and named diabetic der­
mopathy (DD) by Binkley in 1965 [25]. This manifes­
tation, also named shin spots, is the most common 
cutaneous manifestation of DM and it is almost con­
sidered pathognomonic [26]. It has been reported in up 
to 55% of patients, most frequently in males [27­30]. DD 
is observed on the pretibial skin as asymmetric, bilateral 
atrophic and hyperpigmented round­to­oval macules 
and is diagnosed clinically (Figure 2C). Studies suggest 
that DD has a microangiopathic origin [27], which should 
FigURE 1
a. Literature selection process. b. Terms included in the search strategy adjusted for the different databases.
The individual searches conducted on each
manifestation on PubMed, Embase and
Cochrane yielded 6,457 hitsa
A
Articles selected based on title (n = 195)
Exclusion criteria
Published language other than English,
Norwegian, Danish and Swedish 
Studies based on animals, pilot stuides,
reviews, casesb, comorbidities, drugs
aﬀecting skin or poor methodology
Articles selected based on abstract (n = 155)
Further excluded if
More updated studies available
Studies had less participants than others
of same value and conclusion
Cross references 
(n = 2)
Articles selected based on content (n = 89)
Articles selected based on material relevant
to enlighten the aim of this study (n = 34)
Terms included in search
“(Acanthosis nigricans OR skin tags OR skin tag OR acrochordons OR 
acrochordon OR diabetic dermopathy OR dermopathy OR shin spot 
OR shin spots OR necrobiosis lipoidica OR necrobiosis lipoidica 
diabeticorum OR granuloma annulare OR scleroedema diabeticorum 
OR rubeosis faciei OR bullosis diabeticorum OR bullosis OR blister 
OR blisters OR pruritus OR itching) AND (diabetes mellitus OR diabetes 
OR diabetic OR diabetics OR non-insulin dependent diabetes mellitus 
OR Type 2 diabetes mellitus OR Type 1 diabetes mellitus OR insulin 
dependent diabetes OR insulin resistance OR impaired carbohydrate 
metabolism OR hyperinsulinaemia)”.
B
a) The amount of hits contains several duplicates.
b) Bullosis diabeticorum was described in case studies only.
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alert physicians to investigate for other diabetic com­
plications related to the microvasculature including 
retinopathy and peripheral neuropathy. Additionally, 
neuropathy may be an aetiologic factor and it has been 
postulated that patients with peripheral neuropathy are 
more prone to trauma, leading to the development of 
DD lesions [29]. The reduced pain sensation may explain 
why individuals with these lesions tend to neglect the 
presence their lesions. DD has been reported to be asso­
ciated with a number of other diabetic complications, 
which warrants further investigation [27]. Although DD 
is said to be pathognomonic for DM, it should be kept in 
mind that prolonged intake of certain medications such 
as iron­containing drugs, antimalarials and quinolones 
may lead to lesions imitating DD [27, 31].
Rubeosis faciei
First described in the early 19th century as a characteris­
tic reddening of the face (Figure 2D) [32], this manifesta­
tion is particularly prevalent among diabetic Ashkenazi 
Jews [33]. In a recent study, the prevalence of rubeosis 
faciei (RF) was found to be 7% in patients with type 1  
diabetes mellitus (T1DM) [34]. The condition can be ex­
acerbated by hypertension, and the underlying mech­
anism is suggested to be diabetic microangiopathy, 
which results in dilatation of superficial veins. The de­
gree of RF reflects the incidence of DM, and also the se­
verity of microangiopathy [33]. As with ST, many pa­
tients with RF might go undiagnosed. 
Pruritus
This manifestation presents itself as localised or general­
ised itching without visible primary skin lesions [35]. 
Generalised pruritus (PR) has been reported in up to 
50% of patients with DM [36, 37] and can be an initial 
symptom of DM [38]. Many diabetics have involvement 
of the genital and truncal areas [37, 39]. There seems to 
be a correlation between postprandial glucose and gen­
eralised PR in patients with DM; however, no relation­
ship between HbA1c levels and generalised itching has 
been found [37]. Diabetic smokers are predisposed to 
developing PR to a higher degree than non­diabetic 
smokers [35]. Additionally, PR is a marker for poly­
neuropathy as it appears among patients who lack the 
Achilles tendon reflex or patients who present with 
numbness of their soles and palms [39].
granuloma annulare
Colcott Fox was the first to describe granuloma annulare 
(GA) in 1895 [40]. GA may be generalised or localised, 
and the generalised distribution seems to be more pre­
valent in diabetics [41­43]. The skin lesions of GA are 
typically symmetrically distributed along the distal re­
gion of the extremities and sun­exposed skin areas [41]. 
The papular eruption gradually expands with skin­col­
oured or red borders, creating a central involuted crater 
(Figure 2E and Figure 2F). GA was found to be more 
prevalent among adult females [43]. 
The similarities with necrobiosis lipoidica (NL) are 
striking, why many have hypothesised that GA is seen 
prior to this skin disorder [43]. Nevertheless, several 
studies have failed to show an association between GA 
and DM [44­46].  Even so, it has been recommended 
that all individuals presenting with GA should be 
screened for DM, and it was also suggested that indi­
viduals above the age of 30 years with generalised GA 
should be screened annually [42]. 
necrobiosis lipoidica
This condition was originally described by Erich Urbach 
in 1932 [47]. As mentioned above, NL can resemble GA 
and is commonly associated with DM [43]. The patho­
genesis is not clear, but may be explained by microan­
giopathic changes and hypoxia [48­50], although an anti­
body­mediated vasculitis has also been suggested [51]. 
The lesions exhibit the Koebner phenomenon and are 
usually painless although some patients may experience 
itching or pain, especially if the skin lesions ulcerate [52]. 
Studies from the 1960s showed that more than 60% of 
patients with NL had DM and 42% of NL patients were 
undiagnosed diabetics [52, 53]. Subsequent studies, 
however, have found a less obvious correlation [54]. The 
typical lesion is a sharply defined atrophic telangiectatic 
plaque with a glazed content of yellow­brown colour. NL 
is most commonly located pretibially (Figure 2G), and in 
80% of cases it will have a bilateral distribution. Usually, 
diabetics develop lesions in their fourth decade of life 
[54]. The prevalence of NL among diabetics is 0.3%, and 
the condition is more frequent among women. Forty­
three percent of the patients who have this condition 
have a family history of DM [53, 54]. 
scleroedema diabeticorum
The first full clinical description of this scleroederma­like 
KEy POints
The prevalence of diabetes mellitus is increasing.
Skin tags and acanthosis nigricans are both linked to hyperinsulinemia, which is observed in the 
prediabetic state.
Bullosis diabeticorum, diabetic dermopathy and scleroedema diabeticorum are more commonly  
seen in long­standing diabetes.
Patients presenting with diabetic dermopathy should be examined for other diabetic microangiopathies 
including retinopathy and nephropathy.
Early detection and intervention of cutaneous manifestations may improve the prognosis of diabetes.
Identifying these specific cutaneous manifestations should prompt screening for prediabetes and 
diabetes.
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tablE 1
An overview of the included studies.
Reference manifestation study design Participants, n
Akpinar & Dervis, 2012 [20] Skin tags Case­control 192 cases  
104 controls
Allen & Hadden, 1970 [64] Bullosis diabeticorum Case series 5
Bahadursingh et al, 2014 [12] Acanthosis nigricans Cross­sectional 311
Basarab et al, 1995 [62] Bullosis diabeticorum Case report and literature review 1
Brickman et al, 2007 [7] Acanthosis nigricans Cross­sectional 618
Brugler et al, 2011 [29] Diabetic dermopathy Case­control 25 cases with T1DM and DD Control groups: 58 with T1DM  
without diabetic dermopathy and 67 non­diabetics
Cole et al, 1983 [57] Scleredema diabeticorum Prospective study 484 
Demir & Demir, 2002 [22] Skin tags Cross­sectional 120
Gannon & Lynch, 1994 [45] Granuloma annulare Prospective study 23
Gitelson & Wertheimer­Kaplinski, 
1965 [33]
Rubeosis faciei Cross­sectional 150 participants of which 35 were examined during summer 
 
 
Grandhe et al, 2005 [10] Acanthosis nigricans Case­control 150 case  
150 controls
Haim et al, 1973 [41] Granuloma annulare Case­control 52 cases   
52 controls
Kidd et al, 1985 [42] Granuloma annulare Case­control 15 cases   
14 controls
Kluczynik et al, 2012 [14] Acanthosis nigricans Cross­sectional 194 
Ko et al, 2013 [35] Pruritus Cross­sectional 385
Kobaissi et al, 2004 [16] Acanthosis nigricans Cross­sectional 131
Kong et al, 2010 [11] Acanthosis nigricans Cross­sectional 1,730 
Lipsky et al, 2000 [65] Bullosis diabeticorum Case series 12
Mobacken et al,  1970 [44] Granuloma annulare Case­control 30 localized granuloma annulare, 3 disseminated granuloma 
annulare, 9 necrobiosis lipoidica 
Muhlemann & Williams, 1984 [43] Granuloma annulare Retrospective study 557 
Muller & Winkelmann, 1966 [49] Necrobiosis lipoidica Cohort 171 necrobiosis lipoidica diabeticorum participants,  
111 diabetics and 60 non­diabetics
Nebesio et al, 2002 [46] Granuloma annulare Case­control 50 cases   
50 controls
Neilly et al, 1986 [37] Pruritus Case­control 300 cases   
100 control
O’Toole et al, 1999 [54] Necrobiosis lipoidica Retrospective study 65 
Rasi et al, 2007 [19] Skin tags Cross­sectional 104 cases  
94 controls
Sari et al, 2010 [21] Skin tags Case­control 113 cases   
31 controls
Sattar et al, 1988 [56] Scleroedema diabeticorum Case­control 100 diabetic cases   
100 non­diabetic controls
Shah et al, 2014 [23] Skin tags Case­control 110 cases with 1­2 acrochordons  
110 controls
Shemer et al, 1998 [28] Diabetic dermopathy Cross­sectional 173
Stoddart et al, 2002 [13] Acanthosis nigricans Cross­sectional 2,205
Vieira et al, 2013 [15] Acanthosis nigricans Cross­sectional 118 
Wigington et al, 2004 [27] Diabetic dermopathy Cross­sectional 61 
Yamaoka et al, 2009 [39] Pruritus Cross­sectional 2,656 outpatients   
499 inpatients
Zhang et al, 2013 [63] Bullosis diabeticorum Case report and literature review 1
DM = diabetes mellitus; HbA1c = glycated haemoglobin; HOMA­IR = homeostatic model assessment – insulin resistance; T1 = type 1; T2 = type 2. continues 
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tablE 1, cOntinUEd
Table 1, continued.
location & ethnicity comment
Turkey & ­ Oral glucose tolerance test 
Hypertension, metabolic syndrome and DM were seen more frequently in patients with skin tags
Northern Ireland & ­ 5 diabetic patients with disease duration varying 3­19 yrs 
Mostly poorly controlled DM, presenting with bullous skin lesions consistent with bullosis diabeticorum
West Indies & 61.1% East Indians, 24.4%  
African, 14.5% mixed
Acanthosis nigricans higher prevalence among overweight individuals with central obesity, hypercholesterolaemia  
and hypertension
United Kingdom & ­ 84­yr­old T2DM woman with several diabetic complications Gliclazide used as antidiabetic treatment
Chicago & African American and Hispanic Significant association between acanthosis nigricans and DM
Omaha, Nebraska, California & ­ Depicts lower blood flow in diabetic dermopathy patients compared with controls 
California & ­ DM participants underwent punch biopsies Scleredema diabeticorum was more prevalent as necrobiosis lipoidica  
and diabetic dermopathy
Turkey & ­ Fasting serum glucose and in some cases oral glucose tolerance test Skin tags associated with DM
Minnesota & ­ HbA1c was normal in participants and no correlation was found
Israel & Ashkenazi originating from Eastern  
and Central Europe and America, Sephardi from 
Spain, North­Africa, Balkans and Turkey, and  
Orientals from Iraq, Persia and Yemen
Oral glucose tolerance test was applied Positive correlation between rubeosis faciei and DM
India & Indian Darker skin yields a higher risk of acanthosis nigricans 
Israel & Eastern European origin Higher prevalence of granuloma annulare among the diabetic individuals. 
 
Colorado & ­ The oral glucose tolerance test, fasting plasma glucose, 2­h plasma glucose, 1­h serum insulin and the area under  
the curve were all significantly higher in granuloma annulare patients
Brazil & 36.1% white,  
63.4% brown­skinned, 0.5% indigenous
HOMA­IR used Supports the finding of an acanthosis nigricans association with DM Darker skin coloured people are more 
prone for developing acanthosis nigricans
Taiwan & ­ Used a blinded observer Increased postprandial glucose among the pruritus participants, however, HbA1c was normal
California & Hispanic Insulin sensitivity was measured, acanthosis nigricans associated to DM, however, obesity is a primary risk factor
New Mexico & 41.3%, Hispanic, 30.7%, non­His­
panic, 20.9%, African American, 7.1%  other 
Fasting blood glucose along with HOMA­IR used to evaluate the carbohydrate metabolism Showed a positive correlation  
of acanthosis nigricans to DM
Seattle & ­ 8­yr follow­up of 12 diabetic patients with bullosis diabeticorum All had similar skin lesions Is in accordance with other reports
Sweden & ­ The oral glucose tolerance test and cortisone­glucose tolerance test was performed No significant relation between  
granuloma annulare and DM 
United Kingdom & ­ The use of questionnaire and retrospective evaluation of answers 6 out of 88 non­insulin­dependent DM participants  
had granuloma annulare
Minnesota & ­ Oral glucose­ and cortisone glucose tolerance were used Necrobiosis lipoidica shown associated with DM and a  
prediabetic state
Indianapolis & ­ Medical records with information on blood glucose measurements, HbA1c and earlier DM diagnosis was reviewed for  
each participant T2DM seen in 9% of cases No statistical significant correlation was observed 
Scotland & ­ Found significantly more vaginal pruritus among DM  
Ireland & ­ Applied glucose tolerance test Found that 11% of the formerly diagnosed diabetics presented with necrobiosis lipoidica  
at diagnosis 5% had impaired glucose tolerance at time of presentation
Iran & ­ 2­h fasting glucose test applied Skin tags individuals at higher risk for developing DM  
Turkey & ­ Oral glucose tolerance test and fasting plasma insulin levels were applied 
Skin tags individuals more prone to having insulin and lipid disorders
Kuwait & ­ 3 fasting blood glucose measurements on different days Skin pressure test and some performed skin biopsies scleroedema  
diabeticorum patients had longer duration of DM
India & ­ Serum fasting plasma glucose and 2 h oral glucose tolerance tests performed DM risk increased in skin tags individuals
Israel & ­ Prevalence of diabetic dermopathy patients increased with the amount of diabetic complications observed
Oklamaha & Cherokee American Indian Fasting blood glucose and plasma insulin levels were measured Acanthosis nigricans positively associated with DM
Brazil & 33.9% whites, 66.1% non­whites Methods applied were fasting blood glucose levels, plasma insulin, HOMA­IR and Insulin­CT method of radioimmunoassay  
of CIS Bio international Acanthosis nigricans was associated with high mean levels of insulin
California & ­ HbA1c measurements and ultrasound­Doppler used to determine blood flow in lesions Abnormal blood flow suggesting  
microangiopathy
Japan & ­ Study applied HbA1c, Achilles tendon reflex, patient medical history Truncal pruritus significantly more common among  
DM individuals
New Zealand & ­ 56­yr­old male patient with DM complicated with retinopathy, nephropathy and neuropathy, presented with bullous skin lesion
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disease is attributed to Buschke in 1902 [55]. The con­
dition manifests by severe permanent thickening of the 
skin of the posterior neck and upper back. Typically, the 
skin thickening develops over years and presents like 
peau d’orange, resulting in decreased sensation to pain 
and touch in the affected areas (Figure 2I) [56, 57]. Scle­
roedema diabeticorum (SD) is primarily seen in indi­
viduals with long­standing DM. The prevalence of SD 
among T2DM patients is approximately 2.5% [57]. On 
the other hand, more than 90% of those with this lesion 
have DM. A suggested mechanism is the effect of hyper­
glycaemia on collagen in the skin, where skin biopsies of 
diabetics show skin thickening with swollen collagen 
[56]. One consequence of the thickened skin is a re­
duced range of motion especially affecting the upper 
back, shoulder and posterior neck [56, 57]. Others are 
particularly affected on their hands and fingers [58]. In 
these patients, the condition can easily be demonstrated 
by the “prayer sign”, where patients are asked to op­
pose the two hands firmly (Figure 2J) [59, 60]. It is im­
portant to distinguish SD from scleroedema Buschke, 
even though some may use the terms interchangeably. 
Scleroedema Buschke is usually used to describe a post­
infectious condition, which is self­limiting [56]. 
bullosis diabeticorum
The formation of bullae in diabetics was first observed in 
1930 [61]. The condition is not inflammatory, but may 
relate to neuropathy or vascular insufficiency [62]. Bullo­
sis diabeticorum (BD) is described as resembling a blister 
secondary to a burn, without the erythematous sur­
rounding. The condition usually appears spontaneously 
overnight, excluding minor trauma as the causative 
mechanism, and the bullae vary in size from 0.5­10 cm2 
containing sterile fluid (Figure 2K and Figure 2L) [62­64]. 
BD is considered a benign lesion with total remission 
within 5­10 weeks. During the healing process, the fluid 
leaks leaving a darkened crust over the affected area 
which dissolves spontaneously. Most frequently, it is ob­
served as a unilateral lesion involving the foot. None­
theless, bilateral affections as well as multiple lesions 
have been reported, and other regions such as the 
trunk, arms and hands can be affected. The prevalence 
is 0.16% in tertiary care centres, and there is a higher 
prevalence among males with a median age of 65 years 
[62­64]. Typically, patients have longstanding T1DM. 
However, it has also been recognised as a prediabetic 
manifestation. This rare lesion should be identified by 
physicians and lead to appropriate intervention to avoid 
further complications. There is a risk of developing sec­
ondary infection, which may complicate the condition, 
leading to a prolonged healing time [65]. Patients often 
describe the onset of symptoms as a burning sensation 
that later fades away. Recurrence is often observed. It is 
FigURE 2
Skin manifestations of diabetes and prediabetes. Acanthosis nigricans of the neck, the most common lo­
calisation (a). Multiple skin tags with underlying acanthosis nigricans on the lateral aspect of the neck 
(b). Diabetic dermopathy on the shin (c). Rubeosis faciei with reddening of the cheeks and the back of 
the nose (d). Disseminated granuloma annulare on the arm (E) and a more localised form on the hand 
(F). Necrobiosis lipoidica on the shin (g) and an ulcerated variant (h). Scleroedema diabeticorum of the 
back and shoulders (i) and an individual with “prayer sign” (J). Diabetic bullae on the shin (K) and the 
toes (l). 
a
d
b
E
g
K
c
F
h
iJ
l
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important to exclude other bullous entities, making BD a 
diagnosis of exclusion.
discUssiOn
Skins signs are observed among diabetics with variable 
duration and also in the prediabetic state. AN is often 
seen early in the course of the disease, especially when 
an individual has additional risk factors for developing 
DM, including obesity. The majority of included studies 
use HbA1c, fasting plasma glucose measurements and 
homeostatic model assessment. Regardless of the  
methods applied, there is overall agreement that AN is 
significantly associated with DM [10, 12, 16]. Kobaissi 
and coworkers diverted from the other studies by apply­
ing a computer programme (MINMOD) to the obtained 
blood samples to define insulin sensitivity [16]. They 
found a stronger correlation with obesity, and they 
therefore suggested that obesity should be a marker for 
DM. Detection of AN has also been shown to encourage 
discussion between the patient and the clinician leading 
to earlier intervention [5]. Screening is recommended 
due to its inexpensive and non­invasive nature [11, 16]. 
ST and AN are frequently found among diabetics 
and prediabetics and can co­occur. An Iranian case­con­
trol study conducted among 104 patients with ST and 94 
BMI­matched controls showed a higher frequency of DM 
in patients with ST [19]. The study found a significant 
correlation between 30 or more ST and risk of impaired 
carbohydrate metabolism. Akpinar and coworkers did 
not manage to reproduce a statistically significant differ­
ence between patients with ST and controls using fast­
ing plasma glucose levels [20]. The discrepancy may be 
due to the fact that Rasi and coworkers included partici­
pants with 3 ST or more in their cross­sectional study 
making them more likely to document significant differ­
ences. Demir & Demir found a significant correlation of 
ST with hyperinsulinaemia rather than overt DM [22].
We identified no original studies focusing on DD 
and its relation to DM, which may be taken to under­
score the fact that the manifestation is acknowledged as 
pathognomic for DM. Studies on DD lack consistency in 
their methodological approach and clarification of the 
underlying pathophysiology [27, 28, 31]. All the diabetics 
with dermopathic lesions in the included studies showed 
underlying microangiopathy. Thus, an indirect correla­
tion can be deduced from the included studies, as well 
as DD’s function as a marker for diabetic complications 
resulting from microangiopathy.  
Manifestations like RF are easy to recognise when 
the patient is first seen. While prevalence studies show a 
tendency for RF to occur among diabetics, evidence of a 
direct correlation is still lacking. Skin colour, ambient 
temperature, hormonal factors and other skin diseases 
such as rosacea may influence facial redness. Further 
studies are required to elucidate the pathophysiology of 
this phenomenon. 
PR is an unspecific symptom and could be related to 
other causes including, fungal infections. In a Taiwanese 
study, postprandial glucose was found to be significantly 
elevated among patients with generalised PR. To the best 
of our knowledge, this is the only study to date reporting 
on this relation. In contrast, in a cross­sectional study 
from the UK including 100 diabetics with PR [37], no cor­
relation between generalised PR and DM could be dem­
onstrated. However, there was a positive correlation 
with vulvar PR. Both studies had shortcomings in relation 
to testing for autonomic neuropathy, which may influ­
ence perspiration and the perception of sensory signals. 
A matter of concern is the difference in terminology and 
the methods used in the two studies. Even though there 
are disputes regarding the correlation of PR to DM, it 
would be beneficial for physicians to include DM among 
their differential diagnoses when presented with a pa­
tient having unexplained generalised PR. A thorough in­
vestigation of any diabetic person presenting with PR is 
advised as this diffuse symptom is also seen with other 
diseases such as thyroid disorders and lymphoma [66].
There is also a dispute regarding the relation be­
tween GA and DM as recent studies have been unable to 
reproduce the results shown by earlier studies [46].  
The reason for the inconsistency between the results 
achieved in the studies may be that different definitions 
and investigations of DM were used as some used fast­
ing plasma glucose and others used HbA1c. Another point 
of interest is the variable phenotypical presentation of 
GA. It seems to be the generalised form that is linked to 
DM [41, 45]. In summary, there is an insufficient amount 
of studies to properly support any statements regarding 
the degree of correlation between GA and DM.
NL has been linked to DM in earlier studies [53, 54]. 
However, in later studies, participants with NL did not 
suffer from DM. The study by O’Toole et al therefore 
raises the question whether NL is a cutaneous manifes­
tation “of the past” [54]. However, physicians should still 
be aware of this manifestation and its occurrence 
among diabetics. There seems to be no recent studies 
on this subject.  
SD is rarely seen nowadays. It is mainly reported 
among obese diabetics with poorly controlled DM sam­
pled from highly selected populations, e.g. diabetes clin­
ics [56, 57]. Thus, the reported prevalence may be higher 
than among the general diabetic population. None­
theless, the collected data support the notion that SD de­
velops from prolonged exposure of high blood glucose 
on collagen in the skin leading to thickening of the skin.
In contrast to some of the other manifestations, BD 
is specifically reported among diabetics, indicating a 
strong clinical correlation. The occurrence of BD among 
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diabetics is possibly under­recognised as all publications 
on this subject are seemingly case reports or smaller 
case series. A critique of some of these reports is that 
many of the subjects present with comorbidities that 
may contribute to the development of bullae. 
Besides these classically described diabetes mark­
ers, there is increasing knowledge of a correlation be­
tween psoriasis and T2DM  [67]. A systematic review 
and meta­analysis from 2013 suggests an association 
between diabetes and psoriasis and psoriatic arthritis. It 
should be noted that the heterogeneity of the included 
studies raises questions with respect to extrapolation of 
their results. Nonetheless, the evidence to date indi­
cates that physicians should screen patients with psori­
asis for diabetes [68].
strengths and limitations
To the best of our knowledge, this is the first systematic 
review aiming to investigate the role of the different 
skin lesions as markers for the prediabetic state or overt 
DM. The literature search presents an updated picture 
of the available evidence and reveals some issues that 
require further investigation.   
A general critique, which applies to many of the 
studies, is sampling bias. Thus, many of the participants 
were selected from diabetic clinics or other tertiary 
units. Another major critique is the lack of blinding of 
physicians and participants which may both entail fur­
ther bias. An additional important difference is the use 
of inconsistent and incompatible methods. Even though 
current studies are likely to provide an updated view, it 
is important to keep in mind that the older studies bet­
ter reflect the poorly controlled diabetics. 
cOnclUsiOn
The most recent studies demonstrate a strong associ­
ation between DM and the entities of ST and AN. The re­
maining presented manifestations require further inves­
tigation inasmuch as newer studies cannot reproduce 
previous results. However, lack of evidence should not 
prevent physicians from screening patients, as this is a 
low­cost measure and as early detection is beneficial. 
The management of DM has improved markedly over 
the years, and better glycaemic control results in a re­
duction of complications. 
Recognition of cutaneous markers enables an ear­
lier diagnosis of undiagnosed DM and recognition of 
suboptimal management of known disease. Thus, the 
presented skin sigsns should lead to a DM­focused diag­
nostic evaluation. 
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